Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

Bernhard Pilz, Erdenechimeg Shagdarsuren, Maren Wellner, Anette Fiebeler, Ralf Dechend, Petra Gratze, Silke Meiners, David L. Feldman, Randy L. Webb, Ingrid M. Garrelds, A. H.Jan Danser, Friedrich C. Luft, Dominik N. Muller*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

234 Citations (Scopus)

Abstract

We tested the hypothesis that the renin inhibitor aliskiren ameliorates organ damage in rats transgenic for human renin and angiotensinogen genes (double transgenic rat [dTGR]). Six-week-old dTGR were matched by albuminuria (2 mg per day) and divided into 5 groups. Untreated dTGR were compared with aliskiren (3 and 0.3 mg/kg per day)-treated and valsartan (Val; 10 and 1 mg/kg per day)-treated rats. Treatment was from week 6 through week 9. At week 6, all groups had elevated systolic blood pressure (BP). Untreated dTGR showed increased BP (202±4 mm Hg), serum creatinine, and albuminuria (34±5.7 mg per day) at week 7. At week 9, both doses of aliskiren lowered BP (115±6 and 139±5 mm Hg) and albuminuria (0.4±0.1 and 1.6±0.6 mg per day) and normalized serum creatinine. Although high-dose Val lowered BP (148±4 mm Hg) and albuminuria (2.1±0.7 mg per day), low-dose Val reduced BP (182±3 mm Hg) and albuminuria (24±3.8 mg per day) to a lesser extent. Mortality was 100% in untreated dTGR and 26% in Val (1 mg/kg per day) treated rats, whereas in all other groups, survival was 100%. dTGR treated with low-dose Val had cardiac hypertrophy (4.4±0.1 mg/g), increased left ventricular (LV) wall thickness, and diastolic dysfunction. LV atrial natriuretic peptide and β-myosin heavy chain mRNA, albuminuria, fibrosis, and cell infiltration were also increased. In contrast, both aliskiren doses and the high-dose Val lowered BP to a similar extent and more effectively than low-dose Val. We conclude that in dTGR, equieffective antihypertensive doses of Val or aliskiren attenuated end-organ damage. Thus, renin inhibition compares favorably to angiotensin receptor blockade in reversing organ damage in dTGR.

Original languageEnglish
Pages (from-to)569-576
Number of pages8
JournalHypertension
Volume46
Issue number3
DOIs
Publication statusPublished - Sept 2005

Research programs

  • EMC COEUR-01-43-01

Fingerprint

Dive into the research topics of 'Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats'. Together they form a unique fingerprint.

Cite this